**FULLY INTEGRATED PHARMACEUTICAL BUSINESS**

Eisai operates two business units – **Neurology** and **Oncology** – with full value-chain capabilities from R&D to production and distribution to sales and marketing.

**RESEARCH & DEVELOPMENT**

The company **annually invests over 20% of its consolidated revenues into its R&D**¹. Eisai currently has **17 compounds** in clinical development (Phase II or later), which are being evaluated in **30 indications**².

**PARTNERSHIPS**

Eisai has a proven track record of successful collaborations. Current partners include Fortune 500, global biopharma, and global pharmaceutical companies.

---

Eisai’s commitment to the health and well being of people worldwide is embodied in our **human health care** (hhc) mission. To achieve this, every employee must spend time with patients and their families to truly understand their perspectives. These insights give us an understanding of their unique experiences, challenges and emotions, which enable us to develop innovative solutions for the prevention, cure and care of disease. Our **hhc mission**: Putting patients and their families at the heart of everything we do.


– HARUO NAITO, CEO OF EISAI CO., LTD.

In FY2019, Eisai employees in the U.S. took part in **OVER 250 hhc ACTIVITIES**.

---

KEY CORPORATE MILESTONES

1987  Eisai creates R&D presence in Andover, MA
1995  Eisai Inc. is established as a US commercial subsidiary
1996  Introduces field sales force
1997  Launches first product (neurology); begins production/packaging operations in US
2002  Achieves product sales of $1 billion
2006  Starts oncology franchise
2007  Acquires Morphotek Inc. to bolster monoclonal antibody development
2008  Acquires MGI Pharma, Inc., including a manufacturing facility in Baltimore, MD
2010  Establishes sales and marketing subsidiary in Canada
2011  Founds H3 Biomedicine to bolster personalized cancer treatment discovery
2014  Enters into collaboration with Biogen to develop and commercialize investigational Alzheimer’s disease treatments
2016  Establishes Eisai Andover Innovative Medicines (AiM) Institute to discover biology driven precision medicines
2017  Eisai Inc. signs an agreement with Grupo Biotoscana (GBT), granting GBT the exclusive licensing rights to commercialize two oncology and two neurology products throughout most of Latin America. Eisai retains the rights to the two oncology products in Mexico
2018  Signs strategic collaboration for the worldwide co-development and co-commercialization of cancer agent with Merck
2019  Establishes Epochal Precision Anti-Cancer Therapeutics (EPAT) in Exton, PA. EPAT focuses on oncology drug development utilizing Eisai’s unique Antibody-Drug Conjugate (ADC) technology (RESPECT®), proprietary payloads, and bispecific antibodies
2020  Opens Eisai Center for Genetics Guided Dementia Discovery (G2D2). Its mission is to harness the power of human genetics to develop next-generation medicines for Alzheimer’s disease (AD) and other dementias

LIVING human health care: SERVING THE COMMUNITY

As part of our hhc mission, we seek to bring benefits to patients beyond the development of new treatments.

We collaborate with many stakeholders including professional, medical, scientific, patient and civic organizations, which enables us to expand our perspectives and advocate on behalf of patients and healthcare providers. One of Eisai’s key patient advocacy programs is Magnolia, which is designed to help address the challenges patients face every day. The Magnolia program currently has three initiatives:

MAGNOLIA MEALS AT HOME®
provides meals at no cost to eligible patients and families living with all cancer types.

- 2,800+ patients have enrolled in the program
- 250+ employees have signed up to volunteer
- 73,000+ meals have been delivered

MAGNOLIA PAWS FOR COMPASSION®
aims to increase access to animal assistance and the benefits that these animals can provide to those coping with illness.

- 19 puppies sponsored to train as service dogs
- 18 service dogs placement costs covered
- 13 employees’ pets completed therapy dog training program

MEAL TRAIN SPONSORED BY MAGNOLIA is an online calendar that aims to optimize the impact of meal delivery to patients and families living with breast cancer.

- 43,000+ meal trains have been created
- 690,000+ meals organized

Magnolia Meals at Home® is sponsored by Eisai Inc. in collaboration with CancerCare, Cancer Support Community and Meals On Wheels America. Magnolia Meals at Home® is a registered trademark of Eisai Inc. mealTrain® is sponsored by Magnolia in partnership with CancerCare and Cancer Support Community. mealTrain® is a trademark of Meal Train LLC. Magnolia Paws for Compassion® is a partnership among the Epilepsy Foundation, 4 Paws for Ability and Eisai Inc. Magnolia Paws for Compassion® is a registered trademark of Eisai Inc.

Magnolia Paws for Compassion® is a partnership among the Epilepsy Foundation, 4 Paws for Ability and Eisai Inc. Magnolia Paws for Compassion® is a registered trademark of Eisai Inc.

©2020 Eisai Inc. All rights reserved. CORP-US2820 us.eisai.com